Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
146.35
+0.74 (+0.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Why Sarepta Therapeutics Fell 14.7% This Week
October 14, 2021
Investors were unimpressed by the company's clinical and financial news.
Via
The Motley Fool
50 Biggest Movers From Yesterday
October 14, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...
Via
Benzinga
Why Sarepta Therapeutics Tumbled Today
October 13, 2021
Investors weren't wowed by a company update, or by news of a fresh stock issue.
Via
The Motley Fool
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
40 Stocks Moving In Wednesday's Mid-Day Session
October 13, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 13, 2021
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
October 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...
Via
Benzinga
Exposures
Product Safety
A Peek Into The Markets: US Stock Futures Gain Ahead Of CPI, Fed Minutes
October 13, 2021
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the Dow Jones dropped more than 100 points in the previous session. Investors are...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
5 Stocks To Watch For October 13, 2021
October 13, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects JPMorgan Chase & Co. (NYSE: JPM) to report quarterly earnings at $3.00 per share on revenue...
Via
Benzinga
What 5 Analyst Ratings Have To Say About Sarepta Therapeutics
October 12, 2021
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:...
Via
Benzinga
Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements
October 11, 2021
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK...
Via
Benzinga
Sarepta, Codiak Nix Exosome Therapy Development Pact
October 08, 2021
Sarepta Therapeutics Inc (NASDAQ: SRPT) notified Codiak BioSciences Inc (NASDAQ: CDAK) that it would terminate the two-year Research License and Option...
Via
Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021
September 15, 2021
Upgrades For Alcoa Corp (NYSE:
Via
Benzinga
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
September 14, 2021
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector.
Via
Talk Markets
The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More
September 04, 2021
This weekend's Barron's reveals what market strategists recommend for a stock market that likely will struggle this fall. Other featured articles discuss biotech stocks...
Via
Benzinga
'Fast Money Halftime Report' Picks For August 24
August 24, 2021
On CNBC's "Fast Money Halftime Report," Stephanie Link said Aptiv PLC (NYSE: APTV) is worthy of a buy. Jon Najarian bought Sarepta Therapeutics Inc (NASDAQ: SRPT) on...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
August 05, 2021
Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ:
Via
Benzinga
99 Biggest Movers From Yesterday
August 06, 2021
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...
Via
Benzinga
Sarepta Therapeutics (SRPT) Q2 2021 Earnings Call Transcript
August 05, 2021
SRPT earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Stocks That Hit 52-Week Lows On Tuesday
July 27, 2021
During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the largest firm by market cap...
Via
Benzinga
Earnings Scheduled For August 4, 2021
August 04, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to...
Via
Benzinga
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
July 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
July 19, 2021
Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows. Noteworthy Points: The largest company by market cap to set a new 52-week...
Via
Benzinga
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
July 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,...
Via
Benzinga
Topics
Product Recall
Exposures
Legal
Product Safety
PreMarket Prep Recap: The 4 Stocks Dennis Dick Bought Yesterday
June 24, 2021
On Wednesday’s PreMarket Prep, co-hosts Joel Elconin and Dennis Dick discussed the bullish chart setups in several tech stocks. ...
Via
Benzinga
Sarepta's Stock Trading Higher As Duchenne Muscular Dystrophy Gene Therapy Shows Promise In Open-Label Study
May 18, 2021
Sarepta Therapeutics Inc (NASDAQ: SRPT) has announced positive 12-week results from the first 11 participants enrolled in open-label study 9001-103 ENDEAVOR being...
Via
Benzinga
Why Sarepta Might Have Just Reversed Its Fortunes In Gene Therapy
May 18, 2021
Sarepta Therapeutics unveiled promising results Tuesday for a gene therapy that targets a muscle-wasting disease in children — and SRPT stock popped.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.